Suppr超能文献

通过自组装混合纳米囊泡实现肿瘤靶向协同给药以克服耐药性

Tumor Targeting Synergistic Drug Delivery by Self-Assembled Hybrid Nanovesicles to Overcome Drug Resistance.

作者信息

Gong Meng-Qing, Wu Cong, He Xiao-Yan, Zong Jing-Yi, Wu Jin-Long, Zhuo Ren-Xi, Cheng Si-Xue

机构信息

Key Laboratory of Biomedical Polymers of Ministry of Education, Department of Chemistry, Wuhan University, Wuhan, 430072, People's Republic of China.

出版信息

Pharm Res. 2017 Jan;34(1):148-160. doi: 10.1007/s11095-016-2051-9. Epub 2016 Oct 13.

Abstract

PURPOSE

To overcome multi-drug resistance (MDR) in tumor chemotherapy, a polymer/inorganic hybrid drug delivery platform with tumor targeting property and enhanced cell uptake efficiency was developed.

METHOD

To evaluate the applicability of our delivery platform for the delivery of different drug resistance inhibitors, two kinds of dual-drug pairs (doxorubicin/buthionine sulfoximine and doxorubicin/tariquidar, respectively) were loaded in heparin-biotin/heparin/protamine sulfate/calcium carbonate nanovesicles to realize simultaneous delivery of an anticancer drug and a drug resistance inhibitor into drug-resistant tumor cells.

RESULTS

Prepared by self-assembly, the drug loaded hybrid nanovesicles with a mean size less than 210 nm and a negative zeta potential exhibit good stability in serum contained aqueous media. The in vitro cytotoxicity evaluation indicates that hybrid nanovesicles with tumor targeting biotin moieties have an enhanced tumor cell inhibitory effect. In addition, dual-drug loaded hybrid nanovesicles exhibit significantly stronger cell growth inhibition as compared with doxorubicin (DOX) mono-drug loaded nanovesicles due to the reduced intracellular glutathione (GSH) content by buthionine sulfoximine (BSO) or the P-glycoprotein (P-gp) inhibition by tariquidar (TQR).

CONCLUSIONS

The tumor targeting nanovesicles prepared in this study, which can simultaneously deliver multiple drugs and effectively reverse drug resistance, have promising applications in drug delivery for tumor treatments. The polymer/inorganic hybrid drug delivery platform developed in this study has good applicability for the co-delivery of different anti-tumor drug/drug resistance inhibitor pairs to overcome MDR. Graphical Abstract A polymer/inorganic hybrid drug delivery platform with enhanced cell uptake was developed for tumor targeting synergistic drug delivery. The heparin-biotin/heparin/protamine sulfate/calcium carbonate nanovesicles prepared in this study can deliver an anticancer drug and a drug resistance inhibitor into drug-resistant tumor cells simultaneously to overcome drug resistance efficiently.

摘要

目的

为克服肿瘤化疗中的多药耐药性(MDR),开发了一种具有肿瘤靶向性和增强细胞摄取效率的聚合物/无机杂化药物递送平台。

方法

为评估我们的递送平台对不同耐药抑制剂递送的适用性,将两种双药组合(分别为阿霉素/丁硫氨酸亚砜胺和阿霉素/他林洛尔)载入肝素-生物素/肝素/硫酸鱼精蛋白/碳酸钙纳米囊泡中,以实现将一种抗癌药物和一种耐药抑制剂同时递送至耐药肿瘤细胞中。

结果

通过自组装制备的载药杂化纳米囊泡平均尺寸小于210 nm,zeta电位为负,在含血清的水性介质中表现出良好的稳定性。体外细胞毒性评估表明,带有肿瘤靶向生物素部分的杂化纳米囊泡具有增强的肿瘤细胞抑制作用。此外,由于丁硫氨酸亚砜胺(BSO)降低了细胞内谷胱甘肽(GSH)含量或他林洛尔(TQR)抑制了P-糖蛋白(P-gp),与载有阿霉素(DOX)单药的纳米囊泡相比,载有双药的杂化纳米囊泡表现出显著更强的细胞生长抑制作用。

结论

本研究制备的肿瘤靶向纳米囊泡可同时递送多种药物并有效逆转耐药性,在肿瘤治疗的药物递送方面具有广阔的应用前景。本研究开发的聚合物/无机杂化药物递送平台对于共递送不同的抗肿瘤药物/耐药抑制剂组合以克服多药耐药性具有良好的适用性。图形摘要 开发了一种具有增强细胞摄取能力的聚合物/无机杂化药物递送平台用于肿瘤靶向协同药物递送。本研究制备的肝素-生物素/肝素/硫酸鱼精蛋白/碳酸钙纳米囊泡可将一种抗癌药物和一种耐药抑制剂同时递送至耐药肿瘤细胞中,以有效克服耐药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验